Eliglustat

DRUG10 trials

Conditions

Gaucher DiseaseGaucher Disease, Type IIIGaucher's DiseaseGaucher's disease type I; Gaucher's disease type IIIHealthyHematologic MalignancyNeuroblastomaSolid Tumor

Early Phase 1

GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma.

Not yet recruitingNCT07090538

Chinese PLA General HospitalNeuroblastoma

Start: 2025-08-01End: 2027-08-31Target: 10Updated: 2025-07-29

Phase 1

Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults

CompletedNCT01659944

Genzyme, a Sanofi CompanyHealthy

Start: 2012-05-31End: 2012-07-31Updated: 2015-03-23

Taste Evaluation of Different Liquid Formulations With Eliglustat

CompletedNCT02422654

Genzyme, a Sanofi CompanyGaucher Disease

Start: 2015-04-30End: 2015-05-31Updated: 2015-05-27

A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

CompletedNCT02536937

SanofiGaucher Disease

Start: 2015-09-30End: 2017-01-31Updated: 2017-03-08

A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate

CompletedNCT02536911

Genzyme, a Sanofi CompanyGaucher Disease

Start: 2015-09-30End: 2016-12-31Updated: 2017-02-10

GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor

CompletedNCT04944888

Chinese PLA General HospitalHematologic Malignancy, Solid Tumor

Start: 2021-07-01End: 2023-11-30Updated: 2023-12-19

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

CompletedNCT06188325

SanofiGaucher's Disease

Start: 2018-01-01End: 2018-03-26Updated: 2024-01-10

A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth

CompletedNCT06193304

SanofiGaucher's Disease

Start: 2014-08-25End: 2014-09-21Target: 6Updated: 2024-01-05

Phase 3

Open label, two cohort (with and without imiglucerase), multicenter study to evaluate pharmacokinetics, safety, and efficacy of eliglustat in pediatric patients with Gaucher disease type 1 and type 3

CompletedCTIS2024-510751-34-00

Genzyme Corp.Gaucher's disease type I; Gaucher's disease type III

Start: 2019-03-26End: 2025-12-23Target: 23Updated: 2025-12-04

Unknown Phase

Eliglustat on Gaucher Disease Type IIIB

CompletedNCT03519646

National Taiwan University HospitalGaucher Disease, Type III

Start: 2018-04-23End: 2020-09-11Updated: 2022-09-15

Related Papers

Inhibition of glycosphingolipid synthesis with eliglustat in combination with immune checkpoint inhibitors in advanced cancers: preclinical evidence and phase I clinical trial.

2024-08-1421 citations

Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1

Molecular Genetics and Metabolism2019-11-1414 citations